A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Unless the context requires otherwise, the words “MannKind,” “we,” “Company,” “us” and “our” refer to MannKind Corporation and its subsidiaries. We are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, we aim to deliver therapies designed to fit seamlessly into daily life. Our cardiometabolic business is currently comprised of three commercial products: Afrezza (insulin human) Inhalation Powder; Furoscix (furosemide injection); and the V-Go wearable insulin delivery device: •Afrezza is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 349M | 349M | 286M | 199M | 100M | 75M |
| Net Income | 5.9M | 5.9M | 28M | -12M | -87M | -81M |
| EPS | $0.02 | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
| Free Cash Flow | 14M | 14M | 33M | -8.3M | -88M | -73M |
| ROIC | 61.0% | 6.5% | 16.7% | 1.8% | -21.7% | -14.6% |
| Gross Margin | 92.3% | 92.3% | 93.9% | 89.5% | 84.0% | 77.7% |
| Debt/Equity | 0.00 | -7.66 | -0.46 | -0.92 | -0.45 | -0.51 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 39M | 39M | 73M | 8.7M | -64M | -47M |
| Operating Margin | 11.1% | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 293M | 293M | 276M | 298M | 257M | 253M |
MANNKIND CORP passes 1 of 9 quality checks, indicating weak fundamentals.
MANNKIND CORP trades at 132.0x trailing earnings, compared to its 15-year median P/E of 35.4x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 59.4x vs a median of 57.3x. The company's 5-year average gross margin is 87.5%. At current prices, the estimated annualized return to fair value is +40.3%.
MANNKIND CORP (MNKD) has a current P/E ratio of 132.0, compared to its historical median P/E of 35.4. The stock is currently considered Expensive based on its historical valuation range.
MANNKIND CORP (MNKD) has a 5-year average return on invested capital (ROIC) of -2.3%. This is below average and may indicate limited pricing power.
MANNKIND CORP (MNKD) has a market capitalization of $774M. It is classified as a small-cap stock.
MANNKIND CORP (MNKD) does not currently pay a regular dividend.
Based on historical P/E analysis, MANNKIND CORP (MNKD) appears expensive. The current P/E of 132.0 is 273% above its historical median of 35.4. The estimated fair value CAGR (P/E method) is -29.2%.
MANNKIND CORP (MNKD) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
MANNKIND CORP (MNKD) reported annual revenue of $349 million in its most recent fiscal year, based on SEC EDGAR filings.
MANNKIND CORP (MNKD) has a net profit margin of 1.7%. This is a modest margin.
MANNKIND CORP (MNKD) generated $14 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
MANNKIND CORP (MNKD) reported earnings per share (EPS) of $0.02 in its most recent fiscal year.
MANNKIND CORP (MNKD) has a 5-year average gross margin of 87.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for MANNKIND CORP (MNKD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MANNKIND CORP (MNKD) has a book value per share of $-0.17, based on its most recent annual SEC filing.
No recent press releases.